Due to its ability to actively disrupt microtubules, attenuate neutrophil activation and reduce inflammation, oral colchicine is a potentially promising agent for reducing morbidity after cardiac surgery. Imazio and investigators from the COPPS-2 (Colchicine for Prevention of the Postpericardiotomy Syndrome and Postoperative Atrial Fibrillation) study group attempted to determine the efficacy and safety of colchicine to reduce postpericardiotomy syndrome (PPS), postoperative atrial fibrillation (AF) and postoperative pericardial/pleural effusion. The subjects in the study were patients undergoing cardiac surgery drawn from 11 Italian centers.
Colchicine was found to reduce the incidence of PPS, but did not reduce postoperative AF or postoperative pericardial/pleural effusion. However, the ability to generalize these results is limited due to the nature of the selected patient population.
Read the full Concise Critical Appraisal by logging into the SCCM eCommunity. Concise Critical Appraisal is a regular feature aimed at highlighting the best and most relevant literature from a variety of academic journals and encouraging discussion around recent studies and research.